LOXL2 and pachyonychia congenita: LOXL2, a tumor promoter in PC progression, is a biomarker and therapeutic target in PC.22 Herein, we found that salidroside suppressed the expression of entire LOX family members, however, more effectively inhibited LOXL2 in a PC cell line (BxPC‐3) (Figure 1).